© RAD Conference Proceedings. All rights reserved. Biokinetic of 90Y-DOTATOC in human body during treatment of neuroendocrine and medullary thyroid tumors is described in this work. For this purpose, the human body may be represented by 4 compartments: blood, kidneys, urinary bladder and tumor. System of differential equations was developed, whose solution is presented in this paper. The aim is the determination of transfer coefficients between individual compartments for a better estimation of the dose in the tumor and other organs of the human body. A computer program is written in standard Fortran90 programming language
This paper describes the Basic Radionuclide vAlue for Internal Dosimetry (BRAID) code, which was dev...
Background: The aim was to review available biokinetic data, collect own experimental data, and prop...
In this study, the absorbed dose of human organs after injection of 177Lu-DOTATOC was studied based ...
Biokinetic model is a mathematical model which describes the behavior of the 90Y in human body durin...
The thyroid biokinetic model of radioactive I-131 was re-evaluated using a refined nine-compartmenta...
The use of radioisotopes of iodine in the diagnostic and therapy of thyroid diseases is among the ol...
Dosimetry is an indispensable and precious factor in patient treatment planning to minimize the abso...
In this study, 177Lu-DOTATOC was prepared under optimized conditions (radiochemical purity: > 99%, r...
A five-compartmental biokinetic model of I-131 radioiodine based on in-vivo gamma camera scanning re...
Abstract — Models for simulating radionuclide distribution in the human body involve assumptions on ...
Radiopharmaceuticals administered for diagnostic or therapeutic applications in humans are selective...
PET with (18)F-choline ((18)F-FCH) is used in the diagnosis of prostate cancer and its recurrences. ...
PET with F-18-choline (F-18-FCH) is used in the diagnosis of prostate cancer and its recurrences. In...
Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tum...
PET with 18F-choline (18F-FCH) is used in the diagnosis of prostate cancer and its recurrences. In t...
This paper describes the Basic Radionuclide vAlue for Internal Dosimetry (BRAID) code, which was dev...
Background: The aim was to review available biokinetic data, collect own experimental data, and prop...
In this study, the absorbed dose of human organs after injection of 177Lu-DOTATOC was studied based ...
Biokinetic model is a mathematical model which describes the behavior of the 90Y in human body durin...
The thyroid biokinetic model of radioactive I-131 was re-evaluated using a refined nine-compartmenta...
The use of radioisotopes of iodine in the diagnostic and therapy of thyroid diseases is among the ol...
Dosimetry is an indispensable and precious factor in patient treatment planning to minimize the abso...
In this study, 177Lu-DOTATOC was prepared under optimized conditions (radiochemical purity: > 99%, r...
A five-compartmental biokinetic model of I-131 radioiodine based on in-vivo gamma camera scanning re...
Abstract — Models for simulating radionuclide distribution in the human body involve assumptions on ...
Radiopharmaceuticals administered for diagnostic or therapeutic applications in humans are selective...
PET with (18)F-choline ((18)F-FCH) is used in the diagnosis of prostate cancer and its recurrences. ...
PET with F-18-choline (F-18-FCH) is used in the diagnosis of prostate cancer and its recurrences. In...
Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tum...
PET with 18F-choline (18F-FCH) is used in the diagnosis of prostate cancer and its recurrences. In t...
This paper describes the Basic Radionuclide vAlue for Internal Dosimetry (BRAID) code, which was dev...
Background: The aim was to review available biokinetic data, collect own experimental data, and prop...
In this study, the absorbed dose of human organs after injection of 177Lu-DOTATOC was studied based ...